Literature DB >> 25986992

Sickle cell disease is associated with iron mediated hypercoagulability.

Nirmish Shah1, Ian J Welsby, Martha A Fielder, Wayne K Jacobsen, Vance G Nielsen.   

Abstract

Sickle cell disease (SCD) is associated with a significant hypercoagulable state and several hemostatic anomalies have been identified in this disease state. Of interest, SCD patients can become iron overloaded after transfusion, and iron can enhance fibrinogen as a substrate for thrombin, resulting in thrombi that commence coagulation quickly and form rapidly. We hypothesized that SCD patients would display hypercoagulable plasma coagulation kinetics and an iron enhancement of coagulation. After obtaining IRB approval, we assessed coagulation kinetics and iron enhancement with viscoelastic methods in archived, citrated plasma obtained from ambulatory or hospitalized SCD patients (n = 20). All SCD patients had plasmatic hypercoagulability, and 65 % were positive for iron enhancement of coagulation. In conclusion, continuing investigation correlating such viscoelastic data with clinical symptoms may provide insight into the role played by iron in the setting of SCD, including complications such as vaso-occlusive crisis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986992     DOI: 10.1007/s11239-015-1230-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  12 in total

Review 1.  Lessons from the Stroke Prevention Trial in Sickle Cell Anemia (STOP) study.

Authors:  R J Adams
Journal:  J Child Neurol       Date:  2000-05       Impact factor: 1.987

2.  Blood transfusion usage among adults with sickle cell disease - a single institution experience over ten years.

Authors:  Emma Drasar; Norris Igbineweka; Nisha Vasavda; Matthew Free; Moji Awogbade; Marlene Allman; Aleksandar Mijovic; Swee Lay Thein
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

Review 3.  Novel therapies in sickle cell disease.

Authors:  Kenneth I Ataga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

4.  Hemodialysis patients have plasmatic hypercoagulability and decreased fibrinolytic vulnerability: role of carbon monoxide.

Authors:  Ryan W Matika; Vance G Nielsen; Evangelina B Steinbrenner; Amy N Sussman; Machaiah Madhrira
Journal:  ASAIO J       Date:  2014 Nov-Dec       Impact factor: 2.872

5.  Circumstances of death in adult sickle cell disease patients.

Authors:  Deepika S Darbari; Paul Kple-Faget; John Kwagyan; Sohail Rana; Victor R Gordeuk; Oswaldo Castro
Journal:  Am J Hematol       Date:  2006-11       Impact factor: 10.047

Review 6.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

7.  Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.

Authors:  Lanetta Jordan; Patricia Adams-Graves; Julie Kanter-Washko; Patricia A Oneal; Medha Sasane; Francis Vekeman; Christine Bieri; Matthew Magestro; Andrea Marcellari; Mei Sheng Duh
Journal:  Curr Med Res Opin       Date:  2014-12-31       Impact factor: 2.580

8.  Iron-enhanced coagulation is attenuated by chelation: thrombelastographic and ultrastructural analysis.

Authors:  Vance G Nielsen; Etheresia Pretorius
Journal:  Blood Coagul Fibrinolysis       Date:  2014-12       Impact factor: 1.276

9.  Characterization of the hypercoagulable state in patients with sickle cell disease.

Authors:  Nirmish Shah; Courtney Thornburg; Marilyn J Telen; Thomas L Ortel
Journal:  Thromb Res       Date:  2012-09-07       Impact factor: 3.944

10.  Iron depletion: an ameliorating factor for sickle cell disease?

Authors:  P C Giordano; W Huisman; C L Harteveld
Journal:  ISRN Hematol       Date:  2011-07-05
View more
  8 in total

1.  Sonoclot(®)-based method to detect iron enhanced coagulation.

Authors:  Vance G Nielsen; Jon Henderson
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

2.  Ancrod revisited: viscoelastic analyses of the effects of Calloselasma rhodostoma venom on plasma coagulation and fibrinolysis.

Authors:  Vance G Nielsen
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

3.  Effects of red blood cell (RBC) transfusion on sickle cell disease recipient plasma and RBC metabolism.

Authors:  Rachel Culp-Hill; Amudan J Srinivasan; Sarah Gehrke; Reed Kamyszek; Andrea Ansari; Nirmish Shah; Ian Welsby; Angelo D'Alessandro
Journal:  Transfusion       Date:  2018-09-28       Impact factor: 3.157

Review 4.  Sickle cell disease: an inherited thrombophilia.

Authors:  Ted Wun; Ann Brunson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

6.  Effects of repleting organic phosphates in banked erythrocytes on plasma metabolites and vasoactive mediators after red cell exchange transfusion in sickle cell disease.

Authors:  Denise A Lopez Domowicz; Ian Welsby; Charles R Esther; Hongmei Zhu; Robert D Marek; Grace Lee; Nirmish Shah; Jessica L Poisson; Tim J McMahon
Journal:  Blood Transfus       Date:  2020-03-17       Impact factor: 3.443

7.  Metabolic impact of red blood cell exchange with rejuvenated red blood cells in sickle cell patients.

Authors:  Sarah Gehrke; Nirmish Shah; Fabia Gamboni; Reed Kamyszek; Amudan J Srinivasan; Alan Gray; Matthew Landrigan; Ian Welsby; Angelo D'Alessandro
Journal:  Transfusion       Date:  2019-08-05       Impact factor: 3.157

Review 8.  Biomarkers and recent advances in the management and therapy of sickle cell disease.

Authors:  Marilyn J Telen
Journal:  F1000Res       Date:  2015-10-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.